{"id":458582,"date":"2021-03-16T08:33:05","date_gmt":"2021-03-16T12:33:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458582"},"modified":"2021-03-16T08:33:05","modified_gmt":"2021-03-16T12:33:05","slug":"skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/","title":{"rendered":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment"},"content":{"rendered":"
\n

San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (\u201cSKYE\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company\u2019s novel THC prodrug, showed no signs of irritation of the eye using an in vitro<\/em> assay, the EpiOcular TM<\/sup> MTT ET-50. <\/p>\n

The EpiOcular TM<\/sup> MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed. Test materials are then categorized into one of four classifications, ranging from non-irritating to severe\/extreme irritation, which correspond to groupings of the in vivo<\/em> gold standard, the Draize eye test.<\/p>\n

The preclinical findings from this study demonstrate that THCVHS achieved the lowest possible ranking of mild\/non-irritating at each dose range (0.5-2.0%) anticipated to be used in Skye\u2019s upcoming Phase 1 study.<\/p>\n

\u201cOur aim is to develop cannabinoid-derived medicines using rigorous pharmaceutical methods and standards, and we are pleased that these results demonstrate the best possible level of safety and non-irritation of the formulation for our novel prodrug of THC, THCVHS,\u201d said Punit Dhillon, Chief Executive Officer of Skye Bioscience. \u201cIt is important to evaluate the irritation potential of a drug formulation in order to avoid exposing humans to potentially irritating materials during clinical testing and\/or approved use. The data from this study further underpins our confidence in our novel molecule, marking a key step forward as we prepare to enter the clinic later this year.\u201d<\/p>\n

EpiOcularTM<\/sup> is an in vitro<\/em> eye irritation test alternative to animal (in vivo<\/em>) testing using human epithelial cells in a 3D model which closely mimics the histological, morphological, biochemical, and physiological properties of the human corneal epithelium. EpiOcularTM<\/sup> has been used for many years by the industry as a non-animal in vitro<\/em> alternative to the Draize test to assess irritation caused by materials in contact with the eye.<\/p>\n

\n In vitro<\/em> alternatives such as the EpiOcularTM<\/sup> assay, which strongly correlate to the Draize test, have become favored to avoid unnecessary harm to animals. The Draize test is an acute toxicity test devised in 1944 by the U.S. Food and Drug Administration (FDA) in which a test substance is applied to the eye or skin, most commonly of albino rabbits, and monitored for signs of erythema, redness, swelling, discharge, ulceration, hemorrhaging, cloudiness, or blindness in the tested eye.<\/p>\n

Skye is currently advancing manufacturing and formulation work on THCVHS in preparation for entering the clinic later this year. The company anticipates releasing topline data from its first-in-human Phase 1 study of THCVHS for the treatment of glaucoma in early 2022.<\/p>\n

\n About Skye Bioscience, Inc. <\/strong>
\n
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company\u2019s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to currently available drugs. For more information, please visit: www.skyebioscience.com<\/u><\/a>. <\/u><\/p>\n

\n CONTACT<\/strong>\n <\/p>\n

Karam Takhar
VP, Corporate Development & Investor Relations
Email: ir@skyebioscience.com<\/u><\/a>
Phone: (858) 410-0266<\/p>\n

\n FORWARD LOOKING STATEMENTS <\/strong>\n <\/p>\n

This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management\u2019s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including \u201canticipated,\u201d \u201ccontemplates,\u201d \u201cgoal,\u201d \u201cfocus,\u201d \u201caims,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cchallenge,\u201d \u201cpredictable,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cmay\u201d or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye\u2019s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (\u201cSKYE\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company\u2019s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular TM MTT ET-50. The EpiOcular TM MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed. Test materials are then categorized into one of four classifications, ranging from non-irritating to severe\/extreme irritation, which correspond to groupings of the in vivo gold standard, the Draize eye … <\/p>\n

Continue reading “Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSkye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (\u201cSKYE\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company\u2019s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular TM MTT ET-50. The EpiOcular TM MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed. Test materials are then categorized into one of four classifications, ranging from non-irritating to severe\/extreme irritation, which correspond to groupings of the in vivo gold standard, the Draize eye … Continue reading "Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T12:33:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment\",\"datePublished\":\"2021-03-16T12:33:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/\",\"name\":\"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==\",\"datePublished\":\"2021-03-16T12:33:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/","og_locale":"en_US","og_type":"article","og_title":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk","og_description":"San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (\u201cSKYE\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company\u2019s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular TM MTT ET-50. The EpiOcular TM MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed. Test materials are then categorized into one of four classifications, ranging from non-irritating to severe\/extreme irritation, which correspond to groupings of the in vivo gold standard, the Draize eye … Continue reading \"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T12:33:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment","datePublished":"2021-03-16T12:33:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/","name":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==","datePublished":"2021-03-16T12:33:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4NiM0MDY2NDI1IzUwMDA3MDk1Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-biosciences-cannabinoid-derived-drug-candidate-thcvhs-demonstrates-no-eye-irritation-in-preclinical-assessment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Skye Bioscience\u2019s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}